Skip to main content
. 2017 Dec 7;50(4):1140–1148. doi: 10.4143/crt.2017.508

Table 1.

Prognostic factors for distant metastasis-free interval

Variable Univariate
Multivariate
10-Year rate (%) p-value HR (95% CI) p-value
Age (yr)
 < 45 88.1 0.002 1
 ≥ 45 94.4 0.60 (0.39-0.99) 0.049
Menopausal, status
 Premenopausal 91.2 0.141
 Perimenopausal or postmenopausal 94.1
Molecular subtype
 Luminal A 96.8 < 0.001 1
 Luminal B 91.1 2.25 (1.06-4.77) 0.034
 HER2 86.5 4.50 (1.78-11.40) 0.001
 Triple negative 88.9 5.13 (2.20-11.95) < 0.001
T category
 T1 98.1 < 0.001 1
 T2-3 86.8 2.27 (1.12-4.58) 0.023
 T4 76.3 3.68 (1.37-9.87) 0.010
N category
 N0 98.0 < 0.001 1
 N1 92.0 3.44 (1.04-11.37) 0.043
 N2-3 77.7 6.98 (2.06-23.62) 0.002
Histologic grade
 I-II 92.7 < 0.001 1
 III 90.4 0.76 (0.43-1.32) 0.329
Lymphovascular invasion
 No 96.0 < 0.001 1
 Yes 86.9 1.23 (0.71-2.14) 0.466
Primary surgery
 Breast-conserving 96.3 < 0.001 1
 Mastectomy 77.5 1.21 (0.41-3.59) 0.733
Lymph node surgery
 No ALND 97.8 < 0.001 1
 ALND 86.1 1.05 (0.36-3.09) 0.933
Chemotherapy
 No 98.8 < 0.001 1
 Yes 90.5 0.83 (0.23-2.99) 0.778

HR, hazard ratio; CI, confidence interval; HER2, human epidermal growth factor receptor 2; ALND, axillary lymph node dissection.